Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies

Core Insights - Clearmind Medicine Inc. successfully held its inaugural Annual Scientific Advisory Board (SAB) meeting, gathering eight experts in relevant fields to provide strategic guidance on the company's clinical and preclinical programs [1][2]. Group 1: Clinical Development - The SAB focused on Clearmind's lead candidate, 5-Methoxy-2-aminoindane (MEAI), which is currently in Phase 1/2a clinical trials for Alcohol Use Disorder (AUD) [2]. - MEAI was highlighted for its unique pharmacological profile and promising safety data, suggesting potential advantages over emerging GLP-1 therapies, making it a potentially safe, accessible, and cost-effective treatment option [2]. - Preclinical findings indicate MEAI's potential to address not only AUD but also obesity, metabolic syndrome, and mental health challenges faced by veterans [2]. Group 2: Strategic Opportunities - The SAB explored opportunities to strengthen Clearmind's clinical development and potential partnerships, reviewing the company's robust intellectual property portfolio, which includes 31 granted patents worldwide [3]. - Insights from the SAB will guide the company's development strategy as it aims to deliver transformative psychedelic-derived therapies for global health challenges [3]. Group 3: Company Overview - Clearmind is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address major under-treated health problems, including alcohol use disorder [4]. - The company's intellectual property portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents and acquire more intellectual property as needed [5].